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similar to that in adults1. This suggests that drug delivery by inhalation via
pMDI plus spacer is lower in children as compared to adults resulting in
similar exposure due to the lower body size of the paediatric population.
Therefore guideline recommendations of a reduced dosage regimen in
children could be appropriate for DPI administration only.
References: 1. Onhøj J, Thorsson L, Bisgaard H. Lung deposition of
inhaled drugs increases with age. Am J Respir Crit Care Med. 2000;162
(5):1819-22.
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Purpose of the study: Asthmatic adolescents are generally recommended to
be dosed like adults. However, this population is unique in many ways and
limited pharmacokinetic (PK) and pharmacodynamic (PD) data are
available on fixed combinations of inhaled-corticosteroids/long acting
b2-agonists (ICS/LABA). In addition the influence of age on the systemic
exposure of drugs administered via pMDI with or without valved holding
chamber is still not fully elucidated. The aim of the study was to investigate
the PK/PD profile of a fixed dose combination of ICS/LABA pMDI in
asthmatic adolescents with or without valved holding chamber in
comparison to a free combination of licenced pMDI products. A comparison
of adolescent and adult asthmatics was also conducted.
Methods: Open label, randomized, three-way crossover study, on 30
asthmatic adolescents receiving a single dose of the fixed combination
of beclometasone dipropionate (BDP)/formoterol pMDI 100/6mg per
actuation (Foster1) with or without AeroChamber PlusTM or a free
combination of BDP 100mg pMDI (Qvar) plus formoterol 6mg pMDI
(Atimos). An open, parallel arm of 30 asthmatic adults receiving Foster1
was added as a control. All patients received a total single dose of BDP and
formoterol of 400mg and 24mg, respectively. Assessments were performed
over 8 hours.
Results: In adolescents, Foster1 with or without AeroChamberPlusTMwas
equivalent to Qvar1þAtimos1 or Foster1 alone in terms of systemic
exposure (AUC0-t) to beclometasone-17-monopropionate (B17MP, active
metabolite of BDP) and formoterol; 90% confidence intervals (CIs) for the
geometric means ratio fixed/free were all within the 0.80–1.25 range
interval. After treatment with Foster1 the systemic exposure to B17MP and
formoterol was also comparable between adolescents and adults (90% CIs
within 0.78–1.17). The PD profile was equivalent between all treatments in
terms of plasma potassium, plasma glucose, pulse rate and forced expiratory
volume in one-second.
Conclusions: In adolescents the PK and PD of Foster1 with or without
AeroChamberPlusTM, is comparable to that of a free combination of
licensed single entity pMDIs, which have established safety and efficacy
profiles. The findings in adolescents adults were comparable.
Reflections stimulated by the research: These results support the indication
for use of ICS/LABA pMDIs in adolescents at the same dosage as in
adults.
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Introduction: in asthmatic children older than 5 years, the GINA guidelines
2012 update recommend to add inhaled long-acting b2- agonists (LABA)
when the disease is not adequately controlled with inhaled corticosteroids
(ICS) alone. Controlled studies have shown that fixed combination
therapies are as effective as giving each drug separatelyand may increase
patients’ compliance. A paediatric extrafine fixed combination of
beclometasone dipropionate (BDP) and formoterol fumarate (FF) via
pressurizedmetered dose inhaler (pMDI) containing 50mg of BDP and 6mg
of FF per actuation (CHF1535) was developed by Chiesi Farmaceutici
S.p.A. (Parma, Italy).
Methods: in a phase-2, double blind, randomised, active- and placebo-
controlled, 5-period cross-over study, the bronchodilator effect of a single
administration of CHF1535 (2 actuations, total dose BDP 100mg and FF
12mg)was compared to that of a free combination of licensed extrafine BDP
pMDI 50mg (2 actuations, total dose 100mg) plus FF 6mg pMDI
(2 actuations, total dose 12mg) in 56 asthmatic children aged 5
and< 12 years. The primary objective was to demonstrate the non-
inferiority of CHF1535 vs the free combination in terms of forced expiratory
volume during the first second (FEV1) AUC corrected by time over
12 hours following the morning dose (AUC0–12 h) (primary efficacy
variable). Secondary objective was to explore the dose-related efficacy of
different doses of CHF1535 (BDP 50mg/FF 6mg, BDP 100mg/FF 12mg
and BDP 200mg/FF 24mg) in terms of FEV1 AUC0–12 h. All treatments
were administered with AeroChamber Plus spacer device. Safety
was assessed through monitoring of adverse events (AEs), ECG and vital
signs.
Results: the non-inferiority of CHF1535 100/12mg compared to the free
combination of BDP 100mgþFF 12mg in terms of FEV1 AUC0–12 h was
demonstrated (adjusted mean difference (95% CI): 0.004L (0.050,
0.041) as the lower confidence limit of the 95% CI of the adjusted mean
difference was - greater than the non-inferiority limit set at 0.1 L. All
treatment groups showed an increase from pre-dose in mean FEV1 at each
time-point over the period to 12 hours post-dose. A trend towards a dose-
related efficacy response, (FEV1AUC0–12 h) was shown. The comparisons
of each CHF1535 dose vs placebo were: 0.037L (P¼ 0.160), 0.119L
(P< 0.001) and 0.094 (P< 0.001) for CHF1535 50/6, CHF1535 100/12,
CHF1535 200/24, respectively. No serious AEs were reported during the
study and no safety signals were found in terms of ECG and vital signs.
Conclusion: CHF 1535 100/12mg was non-inferior to the free combination
of BDPþFF at the same dose in terms of lung function over the 12-hour
post-dose period and a trend towards a dose-related efficacy response was
seen. All treatments were safe and well tolerated.
Reflections stimulated by the research: according to the above results, the
100/12mg dose was selected for the pivotal phase-3 studies of CHF1535
clinical development.
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